Expression pattern of SVEP1 alternatively-spliced forms

Gene

Volumn 505, Issue 1, 2012, Pages 137-145

  Glait Santar, Chen ^a   Pasmanik Chor, Metsada ^a   Benayahu, Dafna ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

Estrogen; MRNA isoforms; Promoter; TNF

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; CELL ADHESION MOLECULE; ESTROGEN; ESTROGEN RECEPTOR ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; PROTEIN C JUN; SVEP1 PROTEIN; TRANSCRIPTION FACTOR IIB; TRANSCRIPTION FACTOR SP1; TRICHOSTATIN A; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ALTERNATIVE RNA SPLICING; ARTICLE; BREAST ADENOCARCINOMA; BREAST CELL; CHROMATIN IMMUNOPRECIPITATION; COCULTURE; COMPUTER MODEL; CONTROLLED STUDY; DEMETHYLATION; EPIGENETICS; GENE EXPRESSION; HUMAN; HUMAN CELL; MOLECULAR INTERACTION; NUCLEOTIDE SEQUENCE; PREDICTION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; PROTEIN EXPRESSION; TUMOR MICROENVIRONMENT;

ALTERNATIVE SPLICING; ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; CELL ADHESION MOLECULES; CELL LINE, TUMOR; COCULTURE TECHNIQUES; ESTROGENS; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; MICE; PROTEINS; RATS; TRANSCRIPTION FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84863860319     PISSN: 03781119     EISSN: 18790038     Source Type: Journal    
DOI: 10.1016/j.gene.2012.05.015     Document Type: Article

References (56)

1. Balkwill F., Coussens L.M. Cancer: an inflammatory link. Nature 2004, 431:405-406.
2. Barrett-Connor E. Hormone replacement and cancer. Br. Med. Bull. 1992, 48:345-355.
3. Baylin S.B., Ohm J.E. Epigenetic gene silencing in cancer-a mechanism for early oncogenic pathway addiction?. Nat. Rev. Cancer 2006, 6:107-116.
4. Beg A.A., Baltimore D. An essential role for NF-kappaB in preventing TNF-alpha-induced cell death. Science 1996, 274:782-784.
5. Benayahu D. Estrogen effects on protein expressed by marrow stromal osteoblasts. Biochem. Biophys. Res. Commun. 1997, 233:30-35.
6. Benayahu D., Kletter Y., Zipori D., Wientroub S. Bone marrow-derived stromal cell line expressing osteoblastic phenotype in vitro and osteogenic capacity in vivo. J. Cell. Physiol. 1989, 140:1-7.
7. Billups K.L., Sherley J.L., Palladino M.A., Tindall J.W., Roberts K.P. Evidence for E-selectin complement regulatory domain mRNA splice variants in the rat. J. Lab. Clin. Med. 1995, 126:580-587.
8. Chen M., Manley J.L. Mechanisms of alternative splicing regulation: insights from molecular and genomics approaches. Nat. Rev. Mol. Cell Biol. 2009, 10:741-754.
9. Compston J.E. Dependence and oestrogen replacement. Lancet 1992, 339:505.
10. Cybulsky M.I., et al. Alternative splicing of human VCAM-1 in activated vascular endothelium. Am. J. Pathol. 1991, 138:815-820.
11. Feinberg A.P., Ohlsson R., Henikoff S. The epigenetic progenitor origin of human cancer. Nat. Rev. Genet. 2006, 7:21-33.
12. Fu Y.X., Watson G., Jimenez J.J., Wang Y., Lopez D.M. Expansion of immunoregulatory macrophages by granulocyte-macrophage colony-stimulating factor derived from a murine mammary tumor. Cancer Res. 1990, 50:227-234.
13. Fujita, P.A., et al. The UCSC Genome Browser database: update 2011. Nucleic Acids Res. 39, D876-D882.
14. Furukawa Y., Umemoto E., Jang M.H., Tohya K., Miyasaka M., Hirata T. Identification of novel isoforms of mouse L-selectin with different carboxyl-terminal tails. J. Biol. Chem. 2008, 283:12112-12119.
15. Glait-Santar C., Benayahu D. SVEP1 promoter regulation by methylation of CpG sites. Gene 2011, 490:6-14.
16. Glait-Santar C., Benayahu D. Regulation of SVEP1 gene expression by 17beta-estradiol and TNFalpha in pre-osteoblastic and mammary adenocarcinoma cells. J. Steroid Biochem. Mol. Biol. 2012, 130:36-44.
17. Glait-Santar C., Pasmanik-Chor M., Oron-Karni V., Benayahu D. Molecular profiling of functional interactions between pre-osteoblastic and breast carcinoma cells. Genes Cells 2012, 17:302-315.
18. Gunthert U., et al. A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell 1991, 65:13-24.
19. Gupta S. Tumor necrosis factor-alpha-induced apoptosis in T cells from aged humans: a role of TNFR-I and downstream signaling molecules. Exp. Gerontol. 2002, 37:293-299.
20. Hui L., et al. Identification of alternatively spliced mRNA variants related to cancers by genome-wide ESTs alignment. Oncogene 2004, 23:3013-3023.
21. Johnston G.I., Bliss G.A., Newman P.J., McEver R.P. Structure of the human gene encoding granule membrane protein-140, a member of the selectin family of adhesion receptors for leukocytes. J. Biol. Chem. 1990, 265:21381-21385.
22. Jones P.A., Baylin S.B. The fundamental role of epigenetic events in cancer. Nat. Rev. Genet. 2002, 3:415-428.
23. Jones P.A., Laird P.W. Cancer epigenetics comes of age. Nat. Genet. 1999, 21:163-167.
24. Kent W.J., et al. The human genome browser at UCSC. Genome Res. 2002, 12:996-1006.
25. King P.D., Sandberg E.T., Selvakumar A., Fang P., Beaudet A.L., Dupont B. Novel isoforms of murine intercellular adhesion molecule-1 generated by alternative RNA splicing. J. Immunol. 1995, 154:6080-6093.
26. Kirschbaum N.E., Gumina R.J., Newman P.J. Organization of the gene for human platelet/endothelial cell adhesion molecule-1 shows alternatively spliced isoforms and a functionally complex cytoplasmic domain. Blood 1994, 84:4028-4037.
27. Knudsen S. Promoter2.0: for the recognition of PolII promoter sequences. Bioinformatics 1999, 15:356-361.
28. Lande-Diner L., Cedar H. Silence of the genes-mechanisms of long-term repression. Nat. Rev. Genet. 2005, 6:648-654.
29. Landry J.R., Mager D.L., Wilhelm B.T. Complex controls: the role of alternative promoters in mammalian genomes. Trends Genet. 2003, 19:640-648.
30. Lareau L.F., Inada M., Green R.E., Wengrod J.C., Brenner S.E. Unproductive splicing of SR genes associated with highly conserved and ultraconserved DNA elements. Nature 2007, 446:926-929.
31. Litvinov S.V., Velders M.P., Bakker H.A., Fleuren G.J., Warnaar S.O. Ep-CAM: a human epithelial antigen is a homophilic cell-cell adhesion molecule. J. Cell Biol. 1994, 125:437-446.
32. Lynch K.W. Consequences of regulated pre-mRNA splicing in the immune system. Nat. Rev. Immunol. 2004, 4:931-940.
33. Mantovani A., Bussolino F., Dejana E. Cytokine regulation of endothelial cell function. FASEB J. 1992, 6:2591-2599.
34. Mendelsohn M.E., Karas R.H. The protective effects of estrogen on the cardiovascular system. N. Engl. J. Med. 1999, 340:1801-1811.
35. Mundy G.R. Mechanisms of bone metastasis. Cancer 1997, 80:1546-1556.
36. Oursler M.J., Pederson L., Fitzpatrick L., Riggs B.L., Spelsberg T. Human giant cell tumors of the bone (osteoclastomas) are estrogen target cells. Proc. Natl. Acad. Sci. U. S. A. 1994, 91:5227-5231.
37. Ovcharenko I., Nobrega M.A., Loots G.G., Stubbs L. ECR Browser: a tool for visualizing and accessing data from comparisons of multiple vertebrate genomes. Nucleic Acids Res. 2004, 32:W280-W286.
38. Paget S. The distribution of secondary growths in cancer of the breast. Cancer Metastasis Rev. 1989, 8:98-101. (1889).
39. Pajares M.J., Ezponda T., Catena R., Calvo A., Pio R., Montuenga L.M. Alternative splicing: an emerging topic in molecular and clinical oncology. Lancet Oncol. 2007, 8:349-357.
40. Plant A., Tobias J.H. Characterisation of the temporal sequence of osteoblast gene expression during estrogen-induced osteogenesis in female mice. J. Cell. Biochem. 2001, 82:683-691.
41. Plant A., Samuels A., Perry M.J., Colley S., Gibson R., Tobias J.H. Estrogen-induced osteogenesis in mice is associated with the appearance of Cbfa1-expressing bone marrow cells. J. Cell. Biochem. 2002, 84:285-294.
42. Rozen S., Skaletsky H. Primer3 on the WWW for general users and for biologist programmers. Methods Mol. Biol. 2000, 132:365-386.
43. Schwerk C., Schulze-Osthoff K. Regulation of apoptosis by alternative pre-mRNA splicing. Mol. Cell 2005, 19:1-13.
44. Segers V.F., et al. Mesenchymal stem cell adhesion to cardiac microvascular endothelium: activators and mechanisms. Am. J. Physiol. Heart Circ. Physiol. 2006, 290:H1370-H1377.
45. Shefer G., Benayahu D. SVEP1 is a novel marker of activated pre-determined skeletal muscle satellite cells. Stem Cell Rev. 2010, 6:42-49.
46. Shur I., Socher R., Hameiri M., Fried A., Benayahu D. Molecular and cellular characterization of SEL-OB/SVEP1 in osteogenic cells in vivo and in vitro. J. Cell. Physiol. 2006, 206:420-427.
47. Shur I., Zemer-Tov E., Socher R., Benayahu D. SVEP1 expression is regulated in estrogen-dependent manner. J. Cell. Physiol. 2007, 210:732-739.
48. Socher R., Benayahu D. Comparative study using scanning electron techniques for imaging of micro-architecture and antigen appearance. J. Microsc. 2008, 230:233-239.
49. Struhl K., Kadosh D., Keaveney M., Kuras L., Moqtaderi Z. Activation and repression mechanisms in yeast. Cold Spring Harb. Symp. Quant. Biol. 1998, 63:413-421.
50. Thiery J.P. Epithelial-mesenchymal transitions in cancer onset and progression. Bull. Acad. Natl. Med. 2009, 193:1969-1978. (discussion 1978-9).
51. Tobias J.H. The effects of SERMs on the skeleton. J. Endocrinol. Invest. 1999, 22:604-608.
52. Wang Z., et al. Computational analysis and experimental validation of tumor-associated alternative RNA splicing in human cancer. Cancer Res. 2003, 63:655-657.
53. Wren B.G. The effect of oestrogen on the female cardiovascular system. Med. J. Aust. 1992, 157:204-208.
54. Xu Q., Lee C. Discovery of novel splice forms and functional analysis of cancer-specific alternative splicing in human expressed sequences. Nucleic Acids Res. 2003, 31:5635-5643.
55. Yang X., et al. Transcriptional activation of estrogen receptor alpha in human breast cancer cells by histone deacetylase inhibition. Cancer Res. 2000, 60:6890-6894.
56. Yang X., Phillips D.L., Ferguson A.T., Nelson W.G., Herman J.G., Davidson N.E. Synergistic activation of functional estrogen receptor (ER)-alpha by DNA methyltransferase and histone deacetylase inhibition in human ER-alpha-negative breast cancer cells. Cancer Res. 2001, 61:7025-7029.